Skip to content

Iovance Biotherapeutics, Inc. IOVA Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
TG Therapeutics logo
TG TherapeuticsTGTX

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Iovance Biotherapeutics, Inc. (IOVA) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $116.94M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 37.8% year-over-year, from $188.05M to $116.94M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a -24.9% compound annual growth rate (CAGR), from $562.11M to $133.9M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.